The COVID-19 vaccines have been associated with warnings of heart inflammatory issues such as myocarditis. In fact, all of the Scandinavian countries (Denmark, Sweden, Norway, Finland and Iceland) have paused or halted the use of Moderna to better understand the risks associated with this particular mRNA-based vaccine. In what could represent bombshell data a recent entry in the American Heart Association (AHA) journal Circulation authored by the provocative Dr. Steven R. Gundry connects the COVID-19 mRNA vaccines with endothelial inflammatory markers and ACS risk in a foreboding cautionary assessment. A cardiac surgeon by training, Dr. Gundry left traditional medicine to embrace a healthy lifestyle, nutritional/plant-based diets and the microbiome movement—the health of bacterial flora for example. By using a state-of-the-art diagnostic called PULS Cardiac Test the author sought to clinically verify the measurements of multiple protein biomarkers producing a probability score for new Acute Coronary Syndrome (ACS). What are the concerns of Dr. Gundry and why isn’t this kind of information more prevalent? The answers to this real-world study, based on continuous testing of 566 patients should be further investigated.
TrialSite offers a summarized and hopefully simplified snapshot of this recent research conducted with the PULS (Protein Unstable Lesion Signature) Test. Produced by GD Biosciences located in Irvine, California the PULS Test measures the most clinically significant protein biomarkers that measure the body’s immune response to arterial injury. Typically, such injuries contribute to the formation and advancement of cardiac lesions, which over time become unstable and consequently rupture. This becomes a cardiac event.
Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning
Our group has been using the PLUS Cardiac Test (GD Biosciences, Inc, Irvine, CA) a clinically validated measurement of multiple protein biomarkers which generates a score predicting the 5 yr risk (percentage chance) of a new Acute Coronary Syndrome (ACS). The score is based on changes from the norm of multiple protein biomarkers including IL-16, a proinflammatory cytokine, soluble Fas, an inducer of apoptosis, and Hepatocyte Growth Factor (HGF)which serves as a marker for chemotaxis of T-cells into epithelium and cardiac tissue, among other markers. Elevation above the norm increases the PULS score, while decreases below the norm lowers the PULS score.The score has been measured every 3-6 months in our patient population for 8 years. Recently, with the advent of the mRNA COVID 19 vaccines (vac) by Moderna and Pfizer, dramatic changes in the PULS score became apparent in most patients.This report summarizes those results. A total of 566 pts, aged 28 to 97, M:F ratio 1:1 seen in a preventive cardiology practice had a new PULS test drawn from 2 to 10 weeks following the 2nd COVID shot and was compared to the previous PULS score drawn 3 to 5 months previously pre- shot. Baseline IL-16 increased from 35=/-20 above the norm to 82 =/- 75 above the norm post-vac; sFas increased from 22+/- 15 above the norm to 46=/-24 above the norm post-vac; HGF increased from 42+/-12 above the norm to 86+/-31 above the norm post-vac. These changes resulted in an increase of the PULS score from 11% 5 yr ACS risk to 25% 5 yr ACS risk. At the time of this report, these changes persist for at least 2.5 months post second dose of vac.We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination.